OVERVIEW OF THE ZIMBABWE NATIONAL MEDICINES POLICY Dr C E Ndhlovu, M Med Sci, FRCP Chairperson, NMTPAC Deputy Dean, UZCHS National workshop, Jan 22-23,

Slides:



Advertisements
Similar presentations
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
Advertisements

1 WHOs Role in Assuring the Quality Safety and Efficacy of Drugs: Introduction Lembit Rägo, MD, PhD, Coordinator Quality Assurance and Safety: Medicines.
Common/shared responsibilities between jobs.
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Strategies for Working with Countries – Regional and Sub-Regional Perspective and Experiences Essential Drugs and Medicines Policy WHO South-East Asia.
Follow-up after training and supportive supervision The IMAI District Coordinator Course.
World Health Organization
1 Health Care Reform in Hong Kong - Department of Health ’ s Perspective Dr Constance Chan Assistant Director of Health May 2001.
MEDICINES SELECTION & FORMULARY MANAGEMENT
California Department of Public Health Loriann De Martini, Pharm.D. Chief Pharmaceutical Consultant Center for Healthcare Quality Medication Error Reduction.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
Hospital Pharmacy Payam Parchamazad, PharmD Staff Pharmacist
Antibiotic Policy in Ghana; the way forward
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Zambia Pharmacovigilance Action Plan National Plan Revision Proposal Dr Albert Mwango Mrs Bernice MwaleSeptember 2004.
TBS November 4, |1 | AMR and appropriate use of antimicrobials Nicola Magrini and Jane Robertson Policy, Access and Use Team, EMP TBS 4 November.
National Mental Health Programme. Govt of India integrated mental health with other health services at rural level. It is being implemented since 1982.
EDM STRATEGY FOR WORKING WITH COUNTRIES-TANZANIA Rose Shija EDM NPO TANZANIA.
Introduction to Standard 2: Partnering with consumers Advice Centre Network Meeting Nicola Dunbar October 2012.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
National Medicine Policy
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Pharmaceutical Manufacturers Association PMA Status of National Production Capacity of Generic Medicines – Private Sector Perspective Emmanuel Mujuru,
New Zealand Medicines and Medical Devices Safety Authority A business unit of the Ministry of Health.
046:127 Pharmaceutical Management for Underserved Populations  Paper on Current Controversy  Team Assignment: Observational Visits  National Drug Policy/Assessment.
Introduction to Elements of In-Country Drug Management with Focus on TB Drugs Jim Rankin Director, Center for Pharmaceutical Management Management Sciences.
Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Role of Regulation in Optimizing Medicine use KNH/UON Pharmacy Symposium Optimizing Medicine.
NRA in BTSs of the EMR Dr. Nabila E. Metwalli Regional Advisor / Blood Safety WHO / EMRO Cairo, Egypt and Dr. Abdel Aziz Saleh WHO / EMRO Advisor.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
ACCESS TO MEDICINES - POLICY AND ISSUES
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Yemaneberhan Taddesse.  PASDEP(plan of accelerated and sustainable development for the Eradication of poverty) Poverty reduction strategy is the main.
Objective the aim of this project was directly addressing a major health problem for Jordan by producing a guideline as a pilot in which the strengths.
Determinants of Rational Use of Medicines Dr A K Sharma Prof & Head Dept of Pharmacology AFMC, Pune.
Medication Error Reduction Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN LESOTHO REPORT OF DAY 1 Botha Tiheli, Masello.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
BREASTFEEDING CONSULTATIVE MEETING FEEDBACK - TRACK 4 23 AUGUST 2011.
TBS 2008-H. Tata & M. Babaley Mapping and In-depth Assessment of Medicines Procurement and Supply Systems WHO Technical Briefing Seminar 17 th -21 st November.
HEALTH FINANCING MOH - HPG JAHR UPDATE ON POLICIES Eleventh Party Congress -Increase state investment while simultaneously mobilizing social mobilization.
Linking the learning to the National Standards for Safer Better Healthcare Joan Heffernan Inspector Manager Regulation – Healthcare Health Information.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
Concepts of Primary health care Ass.Prof:Dr:Essmat Gemaey
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
RECENT ADVANCES IN PROVISION OF PRIMARY HEALTH CARE BY MISSION ORGANIZATIONS THE EFFECT OF AN EDUCATIONAL INTERVENTION ON USE OF ANTIBIOTICS IN THE TREATMENT.
Resource Creation: Health Technologies in Support of System Development Adham R Ismail, MS, MBA, PhD Biomedical Engineer Department of Health Systems &
Steps for the Integration of Traditional Medicine in the National Health Care Delivery System 18 TH ICASA Special Session on Traditional Medicine 1 st.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
OECD REVIEW OF QUALITY OF HEALTH CARE RAISING STANDARDS: DENMARK Ian Forde Health Policy Analyst OECD Health Division 28 May 2013.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
REDESIGNING ORGANIZATION & MANAGEMENT SYSTEMS (IHSDNs Attributes # 7, 8, 9,10, 11, 12, 13) (IHSDNs Attributes # 7, 8, 9,10, 11, 12, 13) July , 2015.
Unit for Medical Systems and Devices at Ministry of Health
Risk Communication in Medicines
Implementing the guideline
WHO Medicines Work in Countries: The Kenya Example
Champlain LHIN Collaboration
Main findings and recommendations from the UNIDO study on the pharmaceutical sector in Zimbabwe Domestication of TRIPs Flexibilities in National IP Legislation.
How to promote access to medicines in Zimbabwe
Managerial and Regulatory Strategies to Improve Drug Use
AGREEMENT FOR TRANSPARENCY The Case of Mexico
National Medicines Policies
Issues on Dispensing Dr Percy Mahlathi.
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
National Medicines Policies
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
How can we make healthcare purchasing in Kenya more strategic?
Strategies to Improve Drug Use
Presentation transcript:

OVERVIEW OF THE ZIMBABWE NATIONAL MEDICINES POLICY Dr C E Ndhlovu, M Med Sci, FRCP Chairperson, NMTPAC Deputy Dean, UZCHS National workshop, Jan 22-23, 2014

Outline of presentation Discuss the specific objectives of the ZNMP Discuss achievements and highlight challenges

1. Availability Aim to have 100% availability of the V items At primary care level throughout the nation VEN classification to prioritize procurement of medicines CBAS classification Level of use of medicines C medicines - primary health care (clinic) level and should be available at all levels of care. B medicines - district hospital level or secondary and higher levels of care. A medicines are prescribed at provincial or central hospital levels. S medicines -specialist only medicines can be used by specialist physicians only in settings adequate diagnostic and laboratory monitoring facilities.

2. Legislation and Regulation of Medicines and Medical Supplies Through MCAZ, DPS, NMTPAC & relevant stakeholders Use of registered or authorized medicines only “SAFEQUAR” Regular reviews and updates of policies/guidelines TRIPS compliance(2003) Parallel importation allowed Compulsory licensing to promote local production “Bolar provisions” in place

3. Medicine Selection Adoption of the “essential medicines concept” Adoption of primary health approach since 1980 Use of standard treatment guidelines PEDLIZ (1980) Now at EDLIZ (6 th edition/2011) ART guidelines

Principles of the Essential Medicines Concept Majority of health problems treated with a small number of medicines Health professionals in practice use few medicines fewer medicines can be used more rationally Procurement & distribution more efficient with fewer medicines Patients can be better informed when fewer medicines are used

4. Generic Medicines Register, procure, prescribe and dispense “generics” Promote local production of generic medicines

5. Assuring quality, safety and efficacy of medicines Mainly MCAZ functions: Medicines must be “registered” or “authorized” Review and maintain the register E.g. remove “unsafe” medicines Monitor adverse medicines events via Pharmacovigilance and Clinical Trials(PVCT) Committee

6. Production of Medicines within Zimbabwe Promote production of essential medicines Promote production of cost-effective medicines Using current Good Manufacturing Practice(GMP)

7. Information, Advertising and Promotion Provide accurate, unbiased, evidence based medicine information For healthcare workers and the general public Watch out for “unethical” medicine promotion

8. Rational use of medicines Promotion of rational or appropriate prescribing, dispensing and use of medicines For both public and private sectors Promote training in RUM at pre-service and in-service levels Monitor RUM through data collection/ regular surveys

9. Medicines Supply- procurement, distribution and storage Medicine Management cycle

What is NatPharm’s role? “ the government will support the status and viability of the procurement agency and will provide sufficient financial basis for its operations”

10. Other Objectives 10. Economic Strategies 11. Organization, management and coordination of the ZNMP 12. Development of Human Resources 13. Operational and Technical research 14. The National Medicine and Therapeutics Policy Advisory Committee (NMTPAC) Setting up of HMTC 15. National, Regional and International Collaboration

Final objective 16. Trade and Public Health Need to balance IPR and the public health good to ensure/enhance access to essential medicines for public health purposes Allow parallel importation Compulsory licensing Allow exploitation of the “Bolar provisions”

Has Zimbabwe addressed equity? Equity issues arise at least 3 levels international level Zim became TRIPS compliant in 2003: compulsory licensing through the Ministry of Health parallel importation of patented products Bolar provisions national level registration of all medicines insisting on generic labelling of medicines adoption of essential medicines concept training in AMU at pre-graduate and post-graduate levels and community level?? Use of medicines appropriately

Conclusions- Nice to look at ! But how useful are they to us?